GLP-1 receptor agonists in heart failure: how far to expand use?
- PMID: 39222643
- DOI: 10.1016/S0140-6736(24)01763-X
GLP-1 receptor agonists in heart failure: how far to expand use?
Conflict of interest statement
I declare consulting fees from Novartis, Roche Diagnostics, and AnaCardio; research grants from Bayer; and speaker and honoraria from AstraZeneca and Novartis. I am supported by the Swedish Research Council (grant 20180899). I am a Fellow of the European Society of Cardiology, a Fellow of the Heart Failure Association of the European Society of Cardiology, a board member of the Heart Failure Association of the European Society of Cardiology, chair of the Heart Failure Working Group: Frailty Cachexia, and a member of HFpEF & HFmrEF Committee and Digital Health & Patient Care Committee.
Comment on
-
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.Lancet. 2024 Sep 7;404(10456):949-961. doi: 10.1016/S0140-6736(24)01643-X. Epub 2024 Aug 30. Lancet. 2024. PMID: 39222642 Clinical Trial.
References
Publication types
LinkOut - more resources
Full Text Sources